Podcasts about therapeutics

Transcript [Music] For Food Safety in a Minute, I'm Susie Craig. It may surprise you, scientists don't know that much about the naturally occurring chemical make-up of our food. Nutrition research has historically focused on protein, carbohydrates, fats, vitamins and minerals. Though researchers have identified 139,000 molecules in food, scientists do not know if they are absorbed, how they are metabolized in our bodies, to which protein they bind, and what cellular processes they affect. Consider the complexity of the chemicals and food along with the complexity of how our bodies metabolize and use those chemicals. With research focused on chemical mapping of foods paired with artificial intelligence, it's possible nutritional science will be revolutionized, new drugs from food chemicals will be developed. Food is Medicine. From Washington State University Extension, this Food Safety in a Minute. [Music] Resources Menichetti, Giulia, A Barnabas and J. Loscalzo. Chemical Complexity of Food and Implications for Therapeutics. New England Journal of Medicine. https://www.nejm.org/doi/full/10.1056/NEJMra2413243

Joining us on this episode is Tom Neyarapally, co-founder and CEO of Archetype Therapeutics, an exciting new AI-driven company in the drug discovery space. Archetype is an AI-native biotech pioneering the use of generative chemogenomics and patient clinicogenomic data to virtually screen billions of potential drug candidates each day.⁠⁠TPM E47 highlights >⁠⁠⁠⁠⁠⁠⁠⁠Episode 47 links:Archetype TherapeuticsTom Neyarapally on LinkedIn “Exploring a “Patient-First” Path in Drug Discovery”, a LinkedIn article by Tom Neyarapally, Paul McDonagh, and Rafael Rosengarten

In this episode of the RCP Medicine podcast, Professor Ailsa Hart and Dr Eathar Shakweh discuss how to approach managing Inflammatory Bowel Disease (IBD) in the acute medical setting. This is the second episode of a 2-part series, with a focus on Crohn's disease. IBD is a common condition, affecting 1 in 123 people in the UK. The 2024 State of the IBD Care in the UK report highlighted the urgent need to shorten time to diagnosis and initiate early treatment to minimise the risk of IBD-related complications. Acute and general medicine physicians have an important role to play in diagnosing and managing IBD. This podcast will equip medics at all stages of training with the necessary knowledge to approach this heterogenous and complex condition. Professor Hart is Director of IBD Research at St Mark's Hospital, London, United Kingdom and a world-leading expert in IBD. Eathar is an IBD Clinical Research Fellow at St Mark's and Imperial, with a special interest in perianal fistulising Crohn's disease. Crohn's & Colitis UK (CCUK) Websitehttps://crohnsandcolitis.org.uk/This is a valuable resource for patients and healthcare professionals alike, containing a wealth of information on IBD investigation and management.British Society of Gastroenterology (BSG) guidelines on Inflammatory Bowel Disease (IBD) - 2019Lamb, Christopher Andrew et al. “British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults.” Gut vol. 68,Suppl 3 (2019): s1-s106. doi:10.1136/gutjnl-2019-318484https://pubmed.ncbi.nlm.nih.gov/31562236/For interested listeners, these are the national guidelines for IBD diagnosis and management. Please note, the new guidelines for 2025 are pending release.ECCO Guidelines on Therapeutics in Crohn's disease: Medical TreatmentTorres, Joana et al. “ECCO Guidelines on Therapeutics in Crohn's Disease: Medical Treatment.” Journal of Crohn's & colitis vol. 14,1 (2020): 4-22. doi:10.1093/ecco-jcc/jjz180https://pubmed.ncbi.nlm.nih.gov/38877997/ECCO Guidelines on Surgery in Crohn's disease: Surgical TreatmentAdamina, Michel et al. “ECCO Guidelines on Therapeutics in Crohn's Disease: Surgical Treatment.” Journal of Crohn's & colitis vol. 18,10 (2024): 1556-1582. doi:10.1093/ecco-jcc/jjae089https://pubmed.ncbi.nlm.nih.gov/38878002/These are the European Crohn's and Colitis Organisation (ECCO) guidelines on therapeutics in Crohn's disease, divided into medical and surgical treatment.RCPEducation and learning | RCP CreditsMusic bensound.com

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/TRR865. CME/MOC/AAPA credit will be available until June 30, 2026.Mission Possible in Prostate Cancer: Leveraging Genomics, Modern Therapeutics, and Individualized Patient Care In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and ZERO Prostate Cancer. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent medical education grants from AstraZeneca, Bayer HealthCare Pharmaceuticals Inc., and Johnson & Johnson.Disclosure information is available at the beginning of the video presentation.

We love to hear from our listeners. Send us a message.In this episode of Cell & Gene: The Podcast, Host Erin Harris interviews Dr. Gloria Matthews, Chief Medical Officer of Aegle Therapeutics, a clinical-stage regenerative medicine company focused on developing therapies for rare and severe dermatologic and immunologic disorders. Dr. Matthews explains how Aegle is pioneering the use of extracellular vesicles (EVs) derived from mesenchymal stem cells, which offer advantages over traditional cell-based therapies. Their discussion highlights Aegle's lead product, AGLE-102 as well as the regulatory and manufacturing challenges of scaling EV-based therapies. They cover the broader therapeutic potential of EVs in areas such as graft-versus-host disease, ocular, and orthopedic disorders, and more.Subscribe to the podcast!Apple | Spotify | YouTube

From lab curiosity to commercial reality. Here's what happens when moss meets the brutal economics of bioprocessing.In Part 1, you've heard the science behind moss-based protein production. Now comes the real test: Can it survive the gauntlet of regulatory scrutiny, cost pressures, and manufacturing scale-up that crushes most biotech innovations?In Part 2 of this groundbreaking conversation, David Brühlmann and Andreas Schaaf, Managing Director and CSO of Eleva, dive into the nuts and bolts of what it actually takes to commercialize a revolutionary production platform. Andreas doesn't just theorize—he's lived through 15+ years of transforming Eleva from startup concept to clinical-stage reality, navigating every regulatory hurdle and economic challenge along the way.Three game-changing advantages that caught our attention:Process Robustness That Actually Works: While CHO cells throw tantrums over minor parameter shifts, moss maintains consistent product quality even when your bioprocess isn't behaving perfectly; a lifeline for manufacturing teams dealing with real-world variability.Economics That Make CFOs Smile: Forget expensive viral filtration steps and costly human pathogen testing. Moss's plant heritage eliminates these animal-system burdens, directly impacting your bottom line in ways that matter.Operational Simplicity: Variability in process ingredients and streamlined cell banking contribute to long-term cost and operational efficiencies that compound over time.Andreas shares hard-won insights about what it really takes to challenge entrenched bioprocessing orthodoxy, including the regulatory conversations, the economic realities, and his advice for scientists brave enough to pursue game-changing innovations.Ready to understand how disruptive biotechnology actually makes it from bench to bedside?Connect with Andreas Schaaf:LinkedIn: www.linkedin.com/in/andreas-schaaf-b3797716Website: www.elevabiologics.comNext step:Book a free consultation to help you get started on any questions you may have about bioprocessing analytics: https://bruehlmann-consulting.com/callDevelop bioprocessing technologies better, faster, at a fraction of the cost with our 1:1 Strategy Call: The quickest and easiest way to excel biotech technology development. Book your call at www.bruehlmann-consulting.com/call/Support the show

This week on Careers in Discovery, we're joined by Remi-Martin Laberge, Co-founder and Chief Technology Officer of Arda Therapeutics. Remi shares his journey from academic research to building companies, the lessons he learned at Unity Biotechnology, and how Arda is using single-cell sequencing and targeted antibodies to eliminate disease-driving cells in chronic conditions. We talked about the leap from scientist to founder, applying oncology tools beyond cancer, and why curiosity and risk-taking go hand in hand in Biotech.  

Transcript [Music] This is Susie Craig for Food Safety in a Minute. The chemicals in the food we eat are more than the carbohydrates, lipids, protein, vitamins, minerals, and additives listed on a food label. Much more. Researchers at Harvard, Northeastern, and Central European University recently reviewed data from the Nutrition Dark Matter library revealing more than 139,000 chemicals in 3,000 common foods. This is complex, emerging science identifying how the composition of food we eat may influence our health and disease. Currently, about 2,000 chemicals found in food are used as drugs. For instance, the origins of aspirin are traced back to salicylic acid found in willow bark and some fruits and vegetables, including strawberries. Lovastatin is linked to chemicals found in red yeast rice. From Washington State University Extension, this is Food Safety in a Minute. [Music] Resources American Chemistry Council. Chemical SafetyFacts.org. The Sweet Chemistry of Five Summer Fruits (8/18/22). https://www.chemicalsafetyfacts.org/health-and-safety/the-sweet-chemistry-of-five-summer-fruits/. Accessed online 5/29/25. Menichetti, Giulia, A Barnabas and J. Loscalzo. Chemical Complexity of Food and Implications for Therapeutics. New England Journal of Medicine. https://www.nejm.org/doi/full/10.1056/NEJMra2413243

What if the future of "impossible" protein therapeutics is hiding in your backyard?For decades, CHO cells have ruled the biotech kingdom as the undisputed champions of complex protein production. But here's the uncomfortable truth: countless breakthrough therapies are gathering dust on laboratory shelves—not because the science failed, but because traditional hosts can't produce them.Enter moss. Yes, moss. That humble green organism clinging to rocks and trees might just be the biotech industry's best-kept secret.In this eye-opening episode, David Brühlmann sits down with Andreas Schaaf, Managing Director and CSO of Eleva, who's spent over 20 years turning the "impossible" into reality. Andreas didn't just stumble upon moss; he co-developed Eleva's revolutionary moss-based platform from wild concept to commercial-scale game-changer, propelling the company into clinical trials.Here are three reasons why this episode is worth listening to:Moss as a Game Changer: More than a plant, moss is a higher eukaryote with mammalian-like protein production, including post-translational modifications and human-compatible glycosylation.Overcoming Bioprocessing Barriers: CHO cells are the industry gold standard, especially for monoclonal antibodies. But what about the therapeutic proteins that CHO can't handle? Many promising candidates end up shelved—not because the science isn't sound, but because existing production platforms hit their limits.Bioprocessing, Simplified: Moss grows in standard bioreactors using familiar workflows—just with a whole organism instead of suspended cells.Curious about how plant-based systems could solve your protein production challenges? Dive into this episode to discover how moss could revolutionize your approach to challenging proteins; and let us know about your own production hurdles.Connect with Andreas Schaaf:LinkedIn: www.linkedin.com/in/andreas-schaaf-b3797716Website: www.elevabiologics.comNext step:Book a free consultation to help you get started on any questions you may have about bioprocessing analytics: https://bruehlmann-consulting.com/callDevelop bioprocessing technologies better, faster, at a fraction of the cost with our 1:1 Strategy Call: The quickest and easiest way to excel biotech technology development. Book your call at www.bruehlmann-consulting.com/call/Support the show

Je leest het goed. De rijkste man van de wereld heeft miljarden nodig. Geld dat 'ie gebruikt om zijn AI-imperium uit te bouwen. Het moet dé concurrent worden van OpenAI. Een bedrijf dat dan weer écht in oorlog ligt met Microsoft.We hebben het er deze aflevering over. Dan hebben we het ook over die echte oorlog. Die tussen Israël en Iran. In Iran smeken ze president Trump om een wapenstilstand in te lassen, maar daar heeft hij geen trek in. Waardoor de onzekerheid op de beurs (voor jou) nog langer aanhoudt.We ontdekten trouwens dat het ondanks die oorlog prima beleggen is in Tel Aviv. Nou ja prima. Fantastisch. Waarom dat is, je raadt het al: daarvoor moet je toch echt luisteren.Hoor je ook meer over een miljardenovername van Eli Lilly en de handelsdeal die Trump heeft gesloten met de EU. Of was het nu met het Verenigd Koninkrijk? See omnystudio.com/listener for privacy information.

Je leest het goed. De rijkste man van de wereld heeft miljarden nodig. Geld dat 'ie gebruikt om zijn AI-imperium uit te bouwen. Het moet dé concurrent worden van OpenAI. Een bedrijf dat dan weer écht in oorlog ligt met Microsoft.We hebben het er deze aflevering over. Dan hebben we het ook over die echte oorlog. Die tussen Israël en Iran. In Iran smeken ze president Trump om een wapenstilstand in te lassen, maar daar heeft hij geen trek in. Waardoor de onzekerheid op de beurs (voor jou) nog langer aanhoudt.We ontdekten trouwens dat het ondanks die oorlog prima beleggen is in Tel Aviv. Nou ja prima. Fantastisch. Waarom dat is, je raadt het al: daarvoor moet je toch echt luisteren.Hoor je ook meer over een miljardenovername van Eli Lilly en de handelsdeal die Trump heeft gesloten met de EU. Of was het nu met het Verenigd Koninkrijk? See omnystudio.com/listener for privacy information.

Send us a textEnlivex Therapeutics CEO Oren Hershkovitz, PhD joins us on another WTR Small-Cap x Biotech Spotlight crossover episode to talk about how the company's cell therapy, Allocetra, reprograms macrophages to treat inflammatory diseases. We dive into the recent Phase 1 data in knee osteoarthritis and what to expect from the randomized Phase 2 readout later this year, as well as the market opportunity. Listen to learn more about Enlivex Therapeutics and its off-the-shelf cell therapy platform. 

In this episode of Careers in Discovery, we're joined by Markus Gruell, Senior Vice President of Corporate Quality at Autolus, one of the UK's leading CAR-T therapy pioneers. Markus takes us behind the scenes of Autolus' journey from a UCL spinout to a commercial-stage Biopharma company, offering a rare look at how quality underpins every part of the drug development lifecycle. From working across GMP and GCP to collaborating with regulators on novel therapies, Markus shares what it means to lead quality in a fast-moving, high-growth Biotech business. We also explore Markus' personal journey - from pharmacist to QP, and from the NHS to senior leadership - guided by a passion for learning, a commitment to patient safety, and a belief in empowering his team through empathy and integrity. If you're curious about CAR-T, what quality looks like in a next-gen therapy company, or how to build a meaningful leadership career without a traditional plan, this episode is not to be missed.  

Transcript [Music] From Washington State University Extension, this is Food Safety in a Minute Did you know there are at least 360 naturally occurring chemicals in strawberries? Sugars including glucose, fructose, and sucrose, minerals such as potassium, and vitamins including folate and vitamin C. They also contain naturally occurring chemicals, some of which may pose health risks. For example, salicylates can trigger allergic-like reactions. In some soil conditions, strawberries can uptake cadmium or lead in trace amounts. In processed strawberry jam, furan is produced, classified as a possible human carcinogen. Food is chemically complex. A recent article, May 2025 in the New England Journal of Medicine found more than 139,000 chemicals in food. For perspective, the USDA tracks 150 nutritional components, 13 on our labels. There is much to learn. Thanks for listening, I'm Susie Craig. [Music] Resources Menichetti, Giulia, A Barnabas and J. Loscalzo. Chemical Complexity of Food and Implications for Therapeutics. New England Journal of Medicine. https://www.nejm.org/doi/full/10.1056/NEJMra2413243

In this episode, Vera spoke with Chris Ehrlich, CEO at CERo Therapeutics, a company developing next-generation T cell immunotherapies, called chimeric engulfment receptor T cells (CER T). Chris has extensive experience in biotechnology, venture capital and strategic transactions, currently serving as CEO and Chairman of the board since February 2024 and previously as CEO of PBAX. He has held leadership roles at Locust Walk Partners and InterWest Partners, where he was involved in several notable biotech acquisitions, including the sales of Xyphos Biosciences to Astellas and Thar Pharmaceuticals to Grunenthal. Chris also serves on multiple boards, including at Prostate Management Diagnostics, the Peter Michael Foundation and Northwestern University's Kellogg School. Chris has a BA in Government from Dartmouth College and an MBA from the Kellogg Graduate School of Management at Northwestern University, where he is a frequent lecturer. Tune into the episode to hear Chris discuss how the company's approach differs from traditional CAR T-cell therapies, his path from venture capital to the C-suite and what's next in the evolving immunotherapy landscape. For more life science and medical device content, visit the Xtalks Vitals homepage. https://xtalks.com/vitals/ Follow Us on Social Media Twitter: https://twitter.com/Xtalks Instagram: https://www.instagram.com/xtalks/ Facebook: https://www.facebook.com/Xtalks.Webinars/ LinkedIn: https://www.linkedin.com/company/xtalks-webconferences YouTube: https://www.youtube.com/c/XtalksWebinars/featured

“We invest to meet the needs of the customer. What's driving these investments are really the customer partnerships that we're building to make these happen,” explains Arul Ramadurai, Chief Commercial Officer at Axplora.Axplora, a global leader in API small molecule and ADC manufacturing, was formed through the merger of Farmabios, Novasep, and PharmaZell. With 2,400 employees across ten API manufacturing sites in Europe, India and the US, the company has recently accelerated its growth strategy with major investments in high-growth areas like GLP-1 peptides and antibody-drug conjugates (ADCs).In a strategic leadership move to drive this expansion, the company appointed Martin Meeson as its new Chief Executive Officer in April 2024, succeeding Sylke Hassel.In the latest episode of the PharmaSource podcast we interview Arul Ramadurai about the company strategy.Full interview

Good morning from Pharma and Biotech Daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. Metsera's new long-acting amylin injection, met-233i, has shown promising weight loss results over eight months, leading to a rise in shares. Meanwhile, CDC vaccine advisors are either being pushed out or leaving their positions. Other top stories include Sirna's expansion beyond the liver, Keros returning $375 million to investors, and ACIP members receiving termination notices. In vitro cell research is focused on slowing aging and preventing age-related diseases. Updates on Merck's oral PCSK9 inhibitor, Sanofi and Regeneron's Dupixent effectiveness, and Avidity's muscular dystrophy drug are also highlighted.The expansion of RNA therapeutics is discussed, with multiple companies aiming to target small interfering RNA to various organs by 2030. Uniqure's regulatory progress in developing a gene therapy for Huntington's disease has sparked optimism, although past disappointments for patients are noted. Perspective Therapeutics presents new data on neuroendocrine tumor treatment at ASCO25. Concerns about RFK Jr.'s vaccine campaign and its potential to increase distrust in vaccines are raised in the editorial. Cancer news, cell and gene therapy updates, upcoming events, job listings, and a call for reader suggestions on coverage topics are also covered.

Immunic Therapeutics Chief Medical Officer Dr Andreas Muehler joined Steve Darling from Proactive to announce two major developments for the company's lead drug candidate, vidofludimus calcium (IMU-838)—a nuclear receptor-related 1 (Nurr1) activator currently being investigated for the treatment of multiple sclerosis. The company has successfully completed enrollment for both Phase 3 ENSURE trials (ENSURE-1 and ENSURE-2), each designed to assess efficacy, safety, and tolerability of vidofludimus calcium in patients with relapsing multiple sclerosis (RMS). Together, the trials enrolled 2,221 adult RMS patients across more than 100 sites in 15 countries, including the United States, India, Latin America, MENA, and Central and Eastern Europe. Each trial randomized patients in a double-blind fashion to receive either 30 mg of vidofludimus calcium or placebo once daily. The primary endpoint of both trials is time to first relapse over a 72-week period, with secondary endpoints including time to confirmed disability worsening (CDW) using the Expanded Disability Status Scale, Volume of new T2-lesions on MRI and time to sustained clinically relevant cognitive decline. Dr. Muehler emphasized the significance of reaching this enrollment milestone, marking a major step forward in delivering a novel oral treatment option for RMS patients globally. Immunic has also released new secondary endpoint data from its Phase 2 CALLIPER trial in progressive multiple sclerosis (PMS), further highlighting the neuroprotective potential of vidofludimus calcium. Among the 467 PMS patients enrolled, vidofludimus calcium reduced the hazard ratio (HR) for 24-week confirmed disability worsening (24wCDW) by 24% compared to placebo (HR 0.76), based on EDSS measurements. Breakdown by PMS subtype showed a 33% reduction in Primary Progressive, a 19% reduction in non-active Secondary Progressive MS and a 34% reduction in active Secondary Progressive MS These new insights reinforce vidofludimus calcium's broad neuroprotective potential across progressive MS subgroups, where few effective treatment options currently exist. With multiple data readouts anticipated and a global footprint already established, Immunic is taking significant strides toward changing the treatment landscape for both relapsing and progressive forms of MS. #proactiveinvestors #immunicinc #nasdaq #imux #MultipleSclerosis #ClinicalTrials #ENSURETrial #CALLIPERStudy #VidofludimusCalcium #Neuroprotection #BiotechNews #MSResearch #ProactiveInvestors

Acorda Therapeutics, Inc. v. Alkermes plc

Dr. Kilian Kelly, Chief Executive Officer and Managing Director of Cynata Therapeutics, has taken on the challenge of manufacturing stem cell therapies consistently and at scale in order to drive the advancements necessary for the next generation of regenerative medicine. Cynata is employing a novel approach that utilizes a single source of pluripotent stem cells (iPSCs) and mesenchymal cell ancestors (MCAs) to generate mesenchymal stem cells (MSCs). Lead programs are targeting graft-versus-host disease, osteoarthritis, and diabetic wounds, where clinical trials have shown great promise to treat these and other diseases. Kilian explains, "We're a stem cell regenerative medicine company, and what we're trying to do is to change the way that we can manufacture stem cell therapies in a consistent and scalable way. I'm sure many of your listeners have heard about stem cell therapies of various types. The particular type of cells that we're working on are called mesenchymal stem cells or MSCs. They've shown lots of promise for lots of different purposes, but a real challenge has been making these cells consistently, especially when you try to do that at a large scale. We have a unique novel manufacturing platform, which helps us to address that major challenge." "The way that these cells were historically produced and indeed still are produced in most cases is by harvesting cells from, for example, somebody donating bone marrow or adipose tissue, also known as fat. And those approaches have certainly allowed a lot of early-stage clinical trials to be performed, which showed lots of really exciting results. But often what happens is that when you move to a larger scale using such a process, and you try to make much larger quantities of cells, perhaps using many different donors, you start to see a lot of inconsistency. There are a few reasons for this. When you have inconsistency with a product, it's inevitable that you're going to get inconsistent results." "If you have inconsistent results in a clinical trial, it becomes a bit of a lottery, and sometimes you can have very disappointing results that are hard to explain. So we think that's been a really big issue that has caused a lot of problems in the field. And aside from the impact on clinical trial results, we also need to think about the future when these products are available and on the market, and how you can actually, in practical terms, produce enough of these products. So, in a nutshell, I think that is probably the major challenge that the field has faced."  #CynataTherapeutics #StemCellTherapy #RegenerativeMedicine #iPSCs #MSCs #MCAs Cynata.com Download the transcript here  

Dr. Kilian Kelly, Chief Executive Officer and Managing Director of Cynata Therapeutics, has taken on the challenge of manufacturing stem cell therapies consistently and at scale in order to drive the advancements necessary for the next generation of regenerative medicine. Cynata is employing a novel approach that utilizes a single source of pluripotent stem cells (iPSCs) and mesenchymal cell ancestors (MCAs) to generate mesenchymal stem cells (MSCs). Lead programs are targeting graft-versus-host disease, osteoarthritis, and diabetic wounds, where clinical trials have shown great promise to treat these and other diseases. Kilian explains, "We're a stem cell regenerative medicine company, and what we're trying to do is to change the way that we can manufacture stem cell therapies in a consistent and scalable way. I'm sure many of your listeners have heard about stem cell therapies of various types. The particular type of cells that we're working on are called mesenchymal stem cells or MSCs. They've shown lots of promise for lots of different purposes, but a real challenge has been making these cells consistently, especially when you try to do that at a large scale. We have a unique novel manufacturing platform, which helps us to address that major challenge." "The way that these cells were historically produced and indeed still are produced in most cases is by harvesting cells from, for example, somebody donating bone marrow or adipose tissue, also known as fat. And those approaches have certainly allowed a lot of early-stage clinical trials to be performed, which showed lots of really exciting results. But often what happens is that when you move to a larger scale using such a process, and you try to make much larger quantities of cells, perhaps using many different donors, you start to see a lot of inconsistency. There are a few reasons for this. When you have inconsistency with a product, it's inevitable that you're going to get inconsistent results." "If you have inconsistent results in a clinical trial, it becomes a bit of a lottery, and sometimes you can have very disappointing results that are hard to explain. So we think that's been a really big issue that has caused a lot of problems in the field. And aside from the impact on clinical trial results, we also need to think about the future when these products are available and on the market, and how you can actually, in practical terms, produce enough of these products. So, in a nutshell, I think that is probably the major challenge that the field has faced."  #CynataTherapeutics #StemCellTherapy #RegenerativeMedicine #iPSCs #MSCs #MCAs Cynata.com Listen to the podcast here  

Michael Ringel is the Chief Operating Officer of Life Biosciences, a biotechnology company pioneering cellular rejuvenation therapies to reverse and prevent multiple diseases of aging. Michael became COO of Life just a few months ago, but he's been advising the company since 2018. Prior to this year, he was managing director and senior partner at Boston Consulting Group (BCG), where over a 25-year career he focused on R&D and innovation initiatives across the private sector and government. He earned his PhD in biology at Imperial College London and a JD from Harvard Law, and has become an active and highly respected member of the global longevity biotech community.In this episode, Chris and Michael explore Life Biosciences' groundbreaking approach to partial epigenetic reprogramming - the "holy grail" technology that could transform how we age at cellular, tissue, and organism levels. They discuss how this approach taps into the same biology that makes babies young, Life's lead therapeutic candidate ER-100 for eye diseases, and the "pipeline in a pill" concept at the core of the geroscience hypothesis: the idea that enable single interventions based on longevity science could treat multiple age-related diseases simultaneously.The Finer Details:The biology behind partial epigenetic reprogramming and how it differs from full reprogramming to pluripotencyWhy Michael considers partial reprogramming the "holy grail" of longevity interventionsLife Biosciences' lead candidate ER-100 for glaucoma and NAION (non-arteritic anterior ischemic optic neuropathy)The innovative inducible system that allows the therapy to be turned on and off with doxycyclineWhy the eye represents an ideal starting point for reprogramming therapiesThe "pipeline in a pill" concept and geroscience hypothesis - how single interventions could treat multiple age-related diseasesParallels between the emerging longevity field and the massive GLP-1 drug market that many pharma companies missedThe role of philanthropic investment in advancing fundamental longevity researchEvolutionary theories of aging and why aging should be easily manipulableTimeline expectations for moving from single disease treatments to whole-body rejuvenationLinksLife Biosciences company websiteMichael Ringel's ARDD talk

Our guest this week, Lara Campana is SVP of Research & Translational Science and a co-founder of Resolution Therapeutics, a company developing regenerative macrophage therapies for inflammatory and fibrotic diseases. In this episode of Careers in Discovery, Lara shares her journey from medical Biotechnology student in Milan to Biotech executive in the UK, and why she's been fascinated by macrophages ever since a single line in a university lecture hinted at their regenerative potential. We talk about the origins of Resolution, how the company grew from a trio of postdocs in a university lab to a clinical-stage Biotech, and the challenges of leading teams, building culture, and letting go as a founder. Lara also reflects on the mindset shift from academic research to pragmatic, patient-focused drug development - and the lessons she's learned along the way about influence, resilience, and finding space to think.

Leah Rand discusses metrics used to evaluate healthcare access. These ideas are then cross-applied to the issue of resource allocation in Massachusetts for Artificial Intelligence EdTech. Dr. Rand is a Research Scientist with the Program on Regulation, Therapeutics, and Law (PORTAL) at Brigham and Women's Hospital and instructor at the Harvard Medical School Center for Bioethics.This episode is Part 4 of 5 in my capstone project as a Y-Lab Fellow at the Harvard Law School Youth Advocacy & Policy Lab. This podcast is not affiliated with Harvard University or Harvard Law School.This podcast isn't financial, legal, or medical advice, but we do discuss how we might invest our resources in systems and policies for a healthier society. If you'd like to learn more about today's topic and other public policy issues, check out the website: ⁠⁠TheJusticePodcast.com⁠

In this episode of FYI – For Your Innovation, Brett Winton and ARK analyst Nemo Despot sit down with Generate Biomedicines CEO Mike Nally and CFO Jason Silvers to explore how generative AI is transforming the discovery and development of protein-based therapeutics. Founded in 2018 by Flagship Pioneering, Generate Biomedicines is building a “self-driving lab” that combines machine learning, cryo-electron microscopy (cryo-EM), and high-throughput wet lab automation to dramatically accelerate drug development. The conversation dives into how Generate is reimagining protein therapeutics — going beyond trial-and-error methods to a data-first, design-driven model for creating novel medicines. The team discusses the company's proprietary approach to integrating structural biology with functional data, the economic implications of reducing time-to-market from 13 years to under 9, and how their platform could unlock treatments for diseases that have been historically undruggable. They also touch on strategic partnerships, scalability, and how AI is shifting the biotech business model from artisanal science to an industrialized, data-driven enterprise.Key Points From This Episode:00:01:30 Why Generate Biomedicines is rethinking protein drug discovery from first principles00:04:40 How their structure-first approach differs from peers like AbSci and Recursion00:07:04 Using cryo-EM to build proprietary protein interaction datasets00:10:57 Traditional drug discovery is random, expensive, and inefficient — here's how Generate is changing that00:16:58 From concept to clinic in 18–24 months: Accelerating timelines through AI00:20:47 Going beyond efficiency: Unlocking access to undruggable biology00:24:48 Turning cryo-EM into a high-throughput data engine for model training00:31:20 The long-term vision: Patient-specific protein therapeutics00:40:00 Why scalability gives Generate an edge over traditional biotech00:47:52 The future of biotech as a research & development (R&D) sharing economy00:54:19 Adapting fast: Keeping pace with generative AI advances across the stack01:00:16 The KPI (key performance indicator) for platform success: Rate of improvement

Dr. Alipi Bonm, a neuro-oncologist at the Providence Swedish Cancer Institute in Seattle, joins host Dr. Ashwani Rajput to offer up valuable insights into brain cancer, from what to expect to the promising treatment options available that could ease your fears. He also debunks common myths, such as the misconception that cell phones and electrical wires cause brain cancer and highlights promising future treatments. If you or a loved one are affected by brain cancer, discover the support groups available for both patients and caregivers. Don't miss out on this informative and supportive discussion.Dr. Ashwani Rajput BioSee below Do you want to know more?Check out the Providence blog for more information on melanoma and other cancer related topics. Personalized cancer peptide vaccine shows remarkable promise against glioblastomaProvidence Saint John's opens last phase of clinical trial of promising drug for aggressive brain cancerTo learn more about our mission programs and services, go to Providence.org.Follow us on social media to get continued information on other important health care topics. You can  connect with us on LinkedIn, Facebook, TikTok, Instagram and X.For all your healthcare information on the go, download the Providence app. Whether you're tracking symptoms, scheduling appointments, or connecting with your healthcare providers, the Providence app has your back.To learn more about the app, check out the Wellness Brief podcast episode. Wellness Brief: Simplifying Care-There's an App for That.We'd love to hear from you. You can contact us at FutureOfHealthPodcasts@providence.org Dr. Ashwani Rajput BioAshwani Rajput, MD, FACS, joined Providence Swedish in September 2024 as the regional executive medical director (EMD) of the Swedish Cancer Institute. Dr. Rajput comes to us from Johns Hopkins University, where he is a professor of Surgery and Oncology, as well as the director of the Hopkins Kimmel Cancer Center in the Washington, D.C. region. Dr. Rajput completed his medical school, general surgery training, and a post-doctoral fellowship in molecular genetics at Case Western Reserve University in Cleveland, Ohio. He went on to the Roswell Park Comprehensive Cancer Center in Buffalo, N.Y., for a fellowship in Complex General Surgical Oncology (CGSO). There, he was recruited to join the faculty at Roswell Park with appointments in GI Surgical Oncology as well as Pharmacology and Therapeutics. His laboratory investigated the key signal transduction pathways in colorectal metastases using novel orthotopic murine models. In 2009, Dr. Rajput was recruited to the University of New Mexico as the inaugural division chief of Surgical Oncology. During his tenure in New Mexico, he also served as the director of surgical services for the NCI-designated Comprehensive Cancer Center and vice-chair of surgery for academic affairs and faculty development. Under his leadership, an ACGME-approved fellowship in CGSO was created and launched. Throughout his roles in New Mexico and D.C., he has actively addressed cancer health care outcomes and health equity. Under Dr. Rajput's leadership, he will develop and implement a cancer strategic vision and enhance collaboration across our geography. He will oversee the SCI medical directors and partner with the Senior Director of Operations to deliver excellence in cancer care. Dr. Rajput and his wife, Sunita, have four children. Outside of work, he enjoys playing tennis, piano, the arts, and traveling.

What if targeting a single cellular pathway could slow aging and boost immunity? Dr. Joan Mannick, a leading voice in aging science, reveals how mTOR inhibitors may be the future of longevity therapeutics. From her early inspiration to groundbreaking clinical trials, Dr. Mannick explores the role of mTOR in aging, immune response, and antiviral immunity. Learn how selective mTOR inhibition could extend healthspan without compromising muscle mass, improve vaccine response in older adults, and unlock new possibilities in clinical longevity. Learn more about Dr. Joan Mannick: https://www.linkedin.com/in/joan-mannick-8089a614/ - Download Dr. Buck Joffrey's FREE ebook, Living Longer for Busy People: https://ru01tne2.pages.infusionsoft.net/?affiliate=0 Book a FREE longevity coaching consultation with Dr. Buck Joffrey: https://coaching.longevityroadmap.com/

Methylene blue is widely marketed over the counter to the general public as well as to the natural health, health freedom, and freedom communities, often on the internet. It is flooding America.   Some sellers are touting methylene blue as a “miracle” tonic that improves “cognitive function”1 and boosts energy to previously unimagined heights. Some have given live demonstrations on TV and podcasts demonstrating how the oral form hyperactivates some people within 35 minutes of the first dose — a typical stimulant drug rush — which is actually a danger signal for potentially activating them into a dangerous manic episode during future exposures or even more deadly outcomes.   Read the full article here: Methylene Blue is highly neurotoxic to your brain and mind   In reality, methylene blue is a lethal neurotoxin, a poison to the brain. It has the same basic chemical composition and harmful clinical effects as the oldest and most neurotoxic “antidepressants,” the monoamine oxidase inhibitors (MAOIs). It also has similarities to the neurotoxic phenothiazine “antipsychotic” drugs, including the original Thorazine (chlorpromazine), but methylene blue is more stimulating or activating.   Methylene blue is not a miraculous new discovery. It is the opposite. Created in 1876 in a lab — it is the oldest manmade chemical to be used in medicine. But in well over a century, methylene blue has never been FDA-approved for psychiatric purposes. Later, its chemical structure was modified in labs for creating many of the earliest, most neurotoxic psychiatric drugs.   Methylene blue suppresses or destroys forms of the enzyme monoamine oxidase that are used by the brain for controlling or modulating four different powerful neurotransmitters — serotonin, dopamine, norepinephrine, and epinephrine. In short, by crushing monoamine oxidase, methylene blue causes overstimulation of four of the brain's major neurotransmitters, all of which profoundly impact the mind.   After the FDA was created in 1906, methylene blue was grandfathered into the market by the agency as an obscure antidote for methemoglobinemia, but it must be emphasized that the FDA has never tested the safety of methylene blue for any purpose. Furthermore, the FDA, based on its adverse reporting system and scientific reports, has published serious warnings about potentially lethal adverse reactions from methylene blue, especially when combined with numerous other drugs.2   The first MAOIs used as depressants were derived from methylene blue, and they turned out to be so toxic that the first two were quickly taken off the market by the FDA. One caused lethal liver disease, and the other caused hypertensive crises. Methylene blue is known to impair liver function tests and to cause hypertensive crises. Early on, all MAOIs were removed for a while from the international list of approved drugs. Please go to this endnote in my report  for a list of historical and scientific studies about the extraordinary history and the nature of methylene blue and the other MAOIs.3   Psychiatry and the psychopharmaceutical complex are so driven to impose neurotoxins upon our brains ⎯ some MAOI antidepressants remain on the market today. FDA Full Prescribing Information for the existing MAOI antidepressants, readily available online,4 provides quick access to the kinds of adverse effects caused by methylene blue. These FDA documents also provide lists of the foods and of some of the many, many drugs you cannot take with MAOIs, like methylene blue, without risking death from serotonin syndrome or a hypertensive crisis.   Meanwhile, all of America is being made a market for the original mother of them all, methylene blue, without requiring a prescription, with bizarrely distorted claims, and with unlimited supplies handed out as easily as a new caffeinated soda.   All of the three approved MAOIs, as well as methylene blue, carry repeated warnings at the FDA and in the scientific community about causing the two potentially crippling and lethal outcomes, serotonin syndrome and malignant hypertension (see below). These potentially lethal outcomes, as with all MAOIs, become much more serious and higher risk when methylene blue is taken with certain foods such as cheese and bananas, or literally with so many other drugs that it is impossible to memorize them or to keep track of them.   Here is one version of a short summary of the long list of dangerous interactions between MAOIs, including methylene blue, and other drugs and foods, taken from Goodman and Gilman's The Pharmacological Basis of Therapeutics (2018, p. 274):   Monoamine Oxidase Inhibitors   Serotonin syndrome is the most serious drug interaction for the MAOIs (see Adverse Effects). The most common cause of serotonin syndrome in patients taking MAOIs is the accidental coadministration of a SHT reuptake-inhibiting antidepressant or tryptophan. Other serious drug interactions include those with meperidine and tramadol. MAOIs also interact with sympathomimetics such as pseudoephedrine, phenylephrine, oxymetazoline, phenylpropanolamine, and amphetamine; these are commonly found in cold and allergy medication and diet aids and should be avoided by patients taking MAOIs. Likewise, patients on MAOIs must avoid foods containing high levels of tyramine: soy products, dried meats and sausages, dried fruits, home-brewed and tap beers, red wine, pickled or fermented foods, and aged cheeses.   I am presenting this detailed summary in the hope of gaining the immediate attention of people and businesses who are promoting methylene blue and anyone who is unfortunately taking it. Please share this summary or the entire document as widely as possible and with proper attribution.   An extensive article follows, detailing my professional experience in the arena of psychopharmacology. It includes a lengthy scientific analysis with more than two dozen endnotes containing an even greater number of scientific citations.   Read the full article here: Methylene Blue is highly neurotoxic to your brain and mind   End Notes   1 All stimulants from caffeine to Ritalin (methylphenidate) and on to methamphetamine and cocaine, and including MAOIs, can produce subjective feelings of improved concentration or memory, and some short-term studies show a brief improvement. This is caused by obsessive-compulsive mental focusing and is driven by a narrowing of general awareness and judgment.  No FDA-approved stimulants, for example, have been proven to help cognition or academic performance, and all harm the brain long-term.  Here is a study that is negligent in its claims and its lack of warnings about methylene blue that may have encouraged the current epidemic use: https://psychiatryonline.org/doi/full/10.1176/appi.pn.2016.pp8a5 I have researched these issues in multiple scientific papers and books, including Brain-Disabling Treatments in Psychiatry: Drugs, Electroshock, and the Psychopharmaceutical Complex, second edition (2008).  For an easily accessible, comprehensive look at stimulant drug effects, also see my free resource center on children and stimulant medications: https://breggin.com/Childrens-Resources-Center   2 Drug Safety Communication: Serious CNS reactions possible when methylene blue is given to patients taking certain psychiatric medications | FDA and FDA Drug Safety Communication: Updated information about the drug interaction between methylene blue and Drug Safety Podcasts > FDA Drug Safety Podcast for Healthcare Professionals: Updated information about the drug interaction between methylene blue and serotonergic psychiatric medications (methylthioninium chloride) and serotonergic psychiatric medications | FDA and much more comprehensive coverage of methylene blue adverse effects with special warnings for professionals can be found at Methylene Blue Monograph for Professionals – Drugs.com   3 Half_a_century_of_antidepressant_drugs_-20151101-21548-vmvosk-libre.pdf. Also see Methylene Blue: The Long and Winding Road From Stain to Brain: Part 2 – PubMed and Methylene Blue in the Treatment of Neuropsychiatric Disorders – PubMed; and Iproniazid | Antidepressant, Monoamine Oxidase Inhibitor & Mental Health | Britannica; Methylene Blue: The Long and Winding Road From Stain to Brain: Part 2 – PubMed; Monoaminergic neurotransmission: the history of the discovery of antidepressants from 1950s until today – PubMed. These cover the fascinating history of MAOIs and Methylene Blue.    4 The currently approved MAOI antidepressants are phenelzine (Nardil), tranylcypromine (Parnate), selegiline (Eldpryl, Emsam, Zelapar)), and isocarboxazid (Marplan).     ______   Learn more about Dr. Peter Breggin's work: https://breggin.com/   See more from Dr. Breggin's long history of being a reformer in psychiatry: https://breggin.com/Psychiatry-as-an-Instrument-of-Social-and-Political-Control   Psychiatric Drug Withdrawal, the how-to manual @ https://breggin.com/a-guide-for-prescribers-therapists-patients-and-their-families/   Get a copy of Dr. Breggin's latest book: WHO ARE THE “THEY” - THESE GLOBAL PREDATORS? WHAT ARE THEIR MOTIVES AND THEIR PLANS FOR US? HOW CAN WE DEFEND AGAINST THEM? Covid-19 and the Global Predators: We are the Prey Get a copy: https://www.wearetheprey.com/   “No other book so comprehensively covers the details of COVID-19 criminal conduct as well as its origins in a network of global predators seeking wealth and power at the expense of human freedom and prosperity, under cover of false public health policies.”   ~ Robert F Kennedy, Jr Author of #1 bestseller The Real Anthony Fauci and Founder, Chairman and Chief Legal Counsel for Children's Health Defense.

In this episode, we are joined by expert Kenneth A. Richman, professor of philosophy and health care ethics at MCPHS University. Join us as we discuss real-world dilemmas, ethical decision-making frameworks, and how pharmacists can uphold integrity while navigating complex healthcare systems. The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.

Join us for the inaugural episode of "TWAD: Cancer, Cures and Coffee" with Dr. Ashwani Rajput and special guest Dr. Kelly Paulson. In this episode, we dive deep into the topic of Melanoma, one of the most serious types of skin cancer. Dr. Paulson, a medical oncologist at Swedish Cancer Institute First Hill in Seattle, shares her expertise on the importance of early detection, risk factors, and the latest advancements in treatment. Learn how to protect yourself and your loved ones from Melanoma and discover the role of the immune system in fighting cancer. Don't miss this informative and engaging discussion.Dr. Ashwani Rajput BioSee below Do you want to know more?Check out the Providence blog for more information on melanoma and other cancer related topics. ·       Cancer survivor speaks with doctor he credits for saving his life·       Saint Patrick HealthBreak - Skin Cancers·       A year to remember: Advancements, recognition and transitions To learn more about our mission programs and services, go to Providence.org.Follow us on social media to get continued information on other important health care topics. You can  connect with us on LinkedIn, Facebook, TikTok, Instagram and X.For all your healthcare information on the go, download the Providence app. Whether you're tracking symptoms, scheduling appointments, or connecting with your healthcare providers, the Providence app has your back.To learn more about the app, check out the Wellness Brief podcast episode. Wellness Brief: Simplifying Care-There's an App for That. We'd love to hear from you. You can contact us at FutureOfHealthPodcasts@providence.org Dr. Ashwani Rajput BioAshwani Rajput, MD, FACS, joined Providence Swedish in September 2024 as the regional executive medical director (EMD) of the Swedish Cancer Institute. Dr. Rajput comes to us from Johns Hopkins University, where he is a professor of Surgery and Oncology, as well as the director of the Hopkins Kimmel Cancer Center in the Washington, D.C. region. Dr. Rajput completed his medical school, general surgery training, and a post-doctoral fellowship in molecular genetics at Case Western Reserve University in Cleveland, Ohio. He went on to the Roswell Park Comprehensive Cancer Center in Buffalo, N.Y., for a fellowship in Complex General Surgical Oncology (CGSO). There, he was recruited to join the faculty at Roswell Park with appointments in GI Surgical Oncology as well as Pharmacology and Therapeutics. His laboratory investigated the key signal transduction pathways in colorectal metastases using novel orthotopic murine models. In 2009, Dr. Rajput was recruited to the University of New Mexico as the inaugural division chief of Surgical Oncology. During his tenure in New Mexico, he also served as the director of surgical services for the NCI-designated Comprehensive Cancer Center and vice-chair of surgery for academic affairs and faculty development. Under his leadership, an ACGME-approved fellowship in CGSO was created and launched. Throughout his roles in New Mexico and D.C., he has actively addressed cancer health care outcomes and health equity. Under Dr. Rajput's leadership, he will develop and implement a cancer strategic vision and enhance collaboration across our geography. He will oversee the SCI medical directors and partner with the Senior Director of Operations to deliver excellence in cancer care. Dr. Rajput and his wife, Sunita, have four children. Outside of work, he enjoys playing tennis, piano, the arts, and traveling.

Graph Therapeutics combines AI-driven perturbation modeling with multi-omics data to develop targeted therapies for patients with complex immune-mediated diseases who currently lack effective treatment options.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete NCPD/ILNA information, and to apply for credit, please visit us at PeerView.com/VSS865. NCPD/ILNA credit will be available until May 9, 2026.Partners in the Myelofibrosis Journey: Nurse-Patient Alliances for JAKi Standards and Emerging Therapeutics In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Myelofibrosis. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by independent medical education grants from GSK and Incyte Corporation.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete NCPD/ILNA information, and to apply for credit, please visit us at PeerView.com/VSS865. NCPD/ILNA credit will be available until May 9, 2026.Partners in the Myelofibrosis Journey: Nurse-Patient Alliances for JAKi Standards and Emerging Therapeutics In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Myelofibrosis. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by independent medical education grants from GSK and Incyte Corporation.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete NCPD/ILNA information, and to apply for credit, please visit us at PeerView.com/VSS865. NCPD/ILNA credit will be available until May 9, 2026.Partners in the Myelofibrosis Journey: Nurse-Patient Alliances for JAKi Standards and Emerging Therapeutics In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Myelofibrosis. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by independent medical education grants from GSK and Incyte Corporation.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete NCPD/ILNA information, and to apply for credit, please visit us at PeerView.com/VSS865. NCPD/ILNA credit will be available until May 9, 2026.Partners in the Myelofibrosis Journey: Nurse-Patient Alliances for JAKi Standards and Emerging Therapeutics In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Myelofibrosis. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by independent medical education grants from GSK and Incyte Corporation.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete NCPD/ILNA information, and to apply for credit, please visit us at PeerView.com/VSS865. NCPD/ILNA credit will be available until May 9, 2026.Partners in the Myelofibrosis Journey: Nurse-Patient Alliances for JAKi Standards and Emerging Therapeutics In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Myelofibrosis. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by independent medical education grants from GSK and Incyte Corporation.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete NCPD/ILNA information, and to apply for credit, please visit us at PeerView.com/VSS865. NCPD/ILNA credit will be available until May 9, 2026.Partners in the Myelofibrosis Journey: Nurse-Patient Alliances for JAKi Standards and Emerging Therapeutics In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Myelofibrosis. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by independent medical education grants from GSK and Incyte Corporation.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete NCPD/ILNA information, and to apply for credit, please visit us at PeerView.com/VSS865. NCPD/ILNA credit will be available until May 9, 2026.Partners in the Myelofibrosis Journey: Nurse-Patient Alliances for JAKi Standards and Emerging Therapeutics In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Myelofibrosis. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by independent medical education grants from GSK and Incyte Corporation.Disclosure information is available at the beginning of the video presentation.

Vet Watch: Where what you know today will protect everybody tomorrow. Join us for the premiere of Vet Watch—the new podcast from Dr. Christopher Lee, DVM, MPH, DACVPM, designed to bring you real‑world clinical insight. In our first episode, Dr. Lee sits down with board‑certified dermatologist Dr. Alice Jeromin, DVM, RPh, DACVD, to explore how isoxazoline parasiticides have reshaped flea, tick, mite, and other ectoparasite control. Alice Jeromin, RPh, DACVD—Before earning her DVM degree from The Ohio State University, Jeromin graduated from the University of Toledo with a BS in Pharmacy and practiced as a hospital pharmacist. She completed her veterinary dermatology residency with Patrick Breen and dermatopathology training at Procter & Gamble, Miami Valley Labs, as well as a fellowship in human dermatology at Metro Health Medical Center, Cleveland, Ohio with Bryan Davis. Jeromin is currently an adjunct professor at Case Western Reserve University, lecturer at Northeast Ohio College of Pharmacy, and former practice owner of Veterinary Allergy & Dermatology, Inc. She is a former member-at-large on AVMA's Council on Biologicals and Therapeutics as chairman of the supplements and compounding committees. Along with publishing in human and veterinary journals, she authored the dermatology chapter in “Pharmacotherapeutics for Veterinary Dispensing”. Her interests include human-animal comparative dermatology and skin lipid research with publications in both areas.  Because of her pharmacist background of counseling patients, she is a strong believer in client education and maintains her website, www.purrfectpet.com, for clients to be educated with evidence-based information as well as an upcoming podcast "Speaking of Pets" The podcast is geared toward pet owners of allergic pets to provide them with accurate, evidence-based information.

For more information regarding this CME/CE activity and to complete the CME/CE requirements and claim credit for this activity, visit:https://www.mycme.com/courses/psychiatric-therapeutics-in-a-digital-world-10096SummaryIn this PsychTalk podcast/webcast episode, Drs. Gregory Mattingly and Lisa Harding delve into the digital world and breakdown its effects on mental health—both positive and negative. By the end of the episode, learners will have a better understanding of the relationship between screen time, social media, and attention, including clinical pearls for how to harness prescription technology to enhance patient outcomes in ADHD and depression.This podcast was recorded and is being used with permission of the presenters.Learning ObjectivesAt the conclusion of this activity, participants should be better able to:Examine the relationship between social media and attentionIncorporate FDA-authorized digital therapeutics into ADHD and depression management plans based on current clinical evidenceThis activity is accredited for CME/CE CreditThis activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the National Association for Continuing Education (NACE) and GlobalHealthXchange. NACE is accredited by the ACCME to provide continuing medical education for physicians.The National Association for Continuing Education designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.This activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse Practitioners® (AANP) through the joint providership of the National Association for Continuing Education (NACE) and GlobalHealthXchange. NACE is accredited by the AANP as an approved provider of nurse practitioner continuing education. Provider number 121222. This activity is approved for 0.50 contact hours (which does not include hours of pharmacology).For additional information about the accreditation of this program, please contact NACE at info@naceonline.com.Summary of Individual DisclosuresPlease review faculty and planner disclosures here.Disclosure of Commercial SupportThis educational activity is not commercially supported.Please visit http://naceonline.com to engage in more live and on demand CME/CE content.

Alissa Coram and Ed Carson analyze Wednesday's market action and discuss key stocks to watch on Stock Market Today. Learn more about your ad choices. Visit megaphone.fm/adchoices

Today we're heading across the Atlantic to speak to Dr. James Field, CEO of London-based LabGenius Therapeutics.LabGenius has a really exciting mission. James and his team of 60 scientists and engineers believe in the powerful combination of human and artificial intelligence, and are pioneering an ML-driven protein engineering platform - EVA - that can design and execute experiments for the development of next-gen antibodies, including complex multispecifics.LabGenius has already raised over $75m in venture capital and built R&D deals with some major pharma and biotech players. After founding the company in 2012, James was named in Forbes' ‘30 Under 30' list for science and healthcare, and even won Innovator of the Year award from the UK's Biotech & Biological Sciences Research Council. Qualio website:https://www.qualio.com/ Previous episodes:https://www.qualio.com/from-lab-to-launch-podcast Apply to be on the show:https://forms.gle/uUH2YtCFxJHrVGeL8 Music by keldez

In this piece we discuss perioperative medicine with Alana Flexman, an anaesthetist and researcher from Vancouver, Canada, and Maryanne Balkin, an anaesthetist and law graduate from Melbourne, Australia. We explore our guests' career journeys, and gender and equity issues, including unconscious bias and bullying, harassment, and discrimination, in the workplace. Finally we talk about the craziness and joy of continued learning and enquiry. Presented by Andy Cumpstey and Kate Leslie on location at the Annual Scientific Meeting of the Australian and New Zealand College of Anaesthetists and Faculty of Pain Medicine in Cairns, Australia, with their guests, Dr Alana Flexman, Clinical Associate Professor, Department of Anesthesiology, Pharmacology and Therapeutics, University of British Columbia, and St. Paul's Hospital/Providence Health Care, Vancouver, Canada, and Dr Maryanne Balkin, Consultant Anaesthetist, Alfred Health, Melbourne, Australia.

Daniel Locke, M.S., is a dedicated healthcare professional and entrepreneur based in Jacksonville, Florida. He earned his Master of Science in Medical Cannabis Science and Therapeutics from the University of Maryland's School of Pharmacy in May 2024. This advanced education has equipped him with a comprehensive understanding of cannabis pharmacology, chemistry, and clinical applications.In 2017, Daniel founded Compassionate Alternative Care, a veteran-owned medical cannabis consultation firm. The organization is committed to providing personalized guidance and support to patients seeking alternative treatments. Under his leadership, the firm has educated patients on various aspects of medical cannabis, including its chemistry, drug delivery methods, and state and federal regulations. His efforts have positioned Compassionate Alternative Care as a premier practice in North Florida, supporting more than 3,000 patients.Before his work in medical cannabis, Daniel served as a Search and Rescue Swimmer in the United States Navy, demonstrating his commitment to service and helping others. He also founded Locke Roofing Company, where he managed projects, identified business opportunities, and led a team to complete large-scale roofing projects.Daniel's dedication to community service is evident through his role as Purchasing Director and Fundraising Manager for Habitat for Humanity in Jacksonville. In this capacity, he developed budgets for 200 houses annually, managed purchasing operations, hired subcontractors, and secured significant contributions from manufacturers.Throughout his diverse career, Daniel has been recognized for his entrepreneurial spirit, leadership, and advocacy for social justice. He continues to be a catalyst in the cannabis industry, striving to educate patients and healthcare professionals about the benefits and applications of medical cannabis.

What if fat loss could be achieved without impacting metabolism? Recorded live at AIS 2025, Dr. Grant Stevens speaks with Alon Bloomenfeld, Executive Chair of Raziel Therapeutics, about a new class of injectable fat reduction—one that works locally, not systemically. Unlike semaglutide or other metabolic treatments, this lipophilic compound directly destroys fat cells at the site of injection, offering a highly targeted, non-surgical solution for body contouring. With FDA Phase III trials underway, Bloomenfeld shares what sets this breakthrough apart.» Apple Podcasts | https://podcasts.apple.com/us/podcast/technology-of-beauty/id1510898426» Spotify | https://open.spotify.com/show/0hEIiwccpZUUHuMhlyCOAm» Recent episodes | https://www.influxmarketing.com/technology-of-beauty/» Instagram | https://www.instagram.com/thetechnologyofbeauty/» LinkedIn | https://www.linkedin.com/company/the-technology-of-beauty/The Technology of Beauty is produced by Influx Marketing, The Digital Agency for Aesthetic Practices. https://www.influxmarketing.com/Want more aesthetic insights? Subscribe to Next Level Practices, the show where we discuss the ever-changing world of digital marketing and patient acquisition and bring you the latest ideas, strategies, and tactics to help you take your practice to the next level. https://www.influxmarketing.com/next-level-practices/

In the final part of this series, Joseph Parambil, MD, walks us through the approach of managing pulmonary hypertension, reviews the pathophysiology and digs into the mechanisms and the differences in the medications. Intro 0:12 In this episode 0:17 Interview with Joseph Parambil, MD 2:53 Reviewing and clarifying pathophysiology prior to initiating therapeutics 4:13 Evaluating patients in terms of their functional status and how does that play a role in initiating therapies 4:25 Vasoreactivity testing 10:21 The categories of medications 14:40 Endothelin receptor antagonists 37:07 TGF pathway 42:13 Scleroderma patient and treatment 50:19 Do patients get a repeat right-heart catheterization? 55:51 What about the TGF-beta? 56:55 Thank you, Dr. Parambil 58:34 Thanks for listening 59:17 We'd love to hear from you! Send your comments/questions to Dr. Brown at rheuminationspodcast@healio.com. Follow us on Twitter @HRheuminations @AdamJBrownMD @HealioRheum. Disclosures: Brown and Parambil report no relevant financial disclosures. Joseph Parambil, MD, is a staff member in the Respiratory Institute and the director of the HHT Center of Excellence and the Vascular Anomalies Center at the Cleveland Clinic. He is associate professor of medicine at Cleveland Clinic's Lerner College of Medicine. He is certified by the American Board of Internal Medicine with additional specialty certification in pulmonary medicine and critical care medicine.

In this episode, Kevin M. Zinchuk, PharmD, CCRP, Denise Scarpelli, PharmD, MBA, and Jill Blind, PharmD, CCRP, give you a sneak peek into the upcoming Advanced Therapeutics Summit at the 2025 Pharmacy Futures Meeting. Tune in as we highlight key topics—from patient access and financial impact to operational strategies and interdepartmental collaboration—that will equip pharmacy leaders with practical tools to navigate this evolving landscape. Don't miss this preview of one of the most anticipated events of the conference! The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.

In this episode of The Red Light Report, Dr. Mike Belkowski returns fresh from the Health Optimization Summit in Austin, Texas, where he reconnected with the vibrant biohacking community. While the event buzz was exciting, Dr. Mike dives right back into what he does best: breaking down cutting-edge research in mitochondrial health and red light therapy. Key Topics Covered: 1. The Mitochondria–Gut Microbiota–Cardiovascular Axis Dr. Mike reviews a pre-release study that uncovers the two-way relationship between our gut microbes and mitochondrial function. Disruptions here may fuel inflammation and oxidative stress, leading to cardiovascular disease. The fix? Support both systems with red light therapy, methylene blue, probiotics, and lifestyle upgrades. 2. Phytochemicals & Gut Health A second study emphasizes how plant compounds like polyphenols and phytochemicals can rebalance gut flora and reduce inflammation. The takeaway: what we eat shapes our gut — and therefore our aging process and mitochondrial efficiency. 3. Red Light Therapy for the Gut-Brain Axis Dr. Mike explores three new studies showing that red and near-infrared light applied to the abdomen can: • Boost beneficial gut bacteria • Improve cognitive and motor function (even in Parkinson's patients) • Decrease harmful microbes He shares exact dosages and frequencies from the research — including exciting applications of pulsed frequencies (e.g., 700Hz) and intranasal photobiomodulation. 4. BioLight's New Methylene Blue Blend – BioBlue Mike reintroduces his company's enhanced methylene blue product, BioBlue, which includes NMN, colloidal gold/silver, and fulvic acid for boosted mitochondrial absorption and synergy with red light therapy. 5. Mitochondrial Inheritance Bombshell To close the episode, Dr. Mike unpacks a groundbreaking (but still early-stage) study suggesting that mitochondria might not be passed down exclusively from mothers. Some animal studies hint that paternal mitochondrial inheritance might occasionally occur — a potential paradigm shift in mitochondrial genetics. If you found the information in today's episode particularly interesting and/or compelling, please share it with a family member, friend, colleague and/or anyone that you think could benefit and be illuminated by this knowledge. Sharing is caring :) As always, light up your health! - Key Points: 00:00 – Event Recap: Health Optimization Summit 02:14 – Mitochondria-Gut-CVD Crosstalk (Pre-release study) 08:52 – Therapeutics for Gut and Mitochondria 10:41 – Methylene Blue: Brain + Mitochondria 13:42 – Red Light Target Zones for General Health 18:33 – Diet + Phytochemicals for Gut and Aging 22:27 – Red Light Therapy + Gut Microbiome (3 Studies) 32:00 – Pulse Frequencies + Optimization Tips 36:42 – Personalization + Gut/Mitochondria Tie-in 39:14 – Mitochondria Inheritance: Paternal Surprise - Articles referenced in episode: The mitochondria-gut microbiota crosstalk – A novel frontier in cardiovascular diseases Promotion of Healthy Aging Through the Nexus of Gut Microbiota and Dietary Phytochemicals Photobiomodulation of gut microbiota with low-level laser therapy: a light for treating neuroinflammation Research progress on paternal mitochondrial inheritance: An overview - Upcoming BioLight Events:   Biohacking Conference - May 28 - 30 (Austin, TX)   Returning to Nature (Quantum Health Retreat), June 26 - 27 (Franklin, TN) - Save 25% when you Subscribe & Save to a BioBundle!   For a BioBundle, you choose:1.) Any one BioBlue supplement(BioBlue, BioBlue (SR), BioBlue Leuco, BioBlue Calm, BioBlue Capsules or BioBlue Leuco Capsules)2.) Any one BioC60 supplement(Regular or Concentrated)   The BioBundle automatically saves you 15% on both of the supplements you choose.You save an additional 10% by choosing to Subscribe & Save to that BioBundle.The 25% savings is passed along for every monthly delivery of your BioBundle!No discount code necessary!   Click here to check out The BioBundle - Dr. Mike's #1 recommendations: Water products: Water & Wellness Grounding products: Earthing.com EMF-mitigating products: Somavedic Blue light-blocking glasses: Ra Optics - Stay up-to-date on social media: Dr. Mike Belkowski: Instagram LinkedIn   BioLight: Website Instagram YouTube Facebook

What if optimizing your fitness and losing weight came down to peptides? In episode 1133 of Mark Bell's Power Project Podcast, Mark Bell, Nsima Inyang, and Justin Kirkland discuss how GLP-1 peptides are transforming fitness and health. Justin explains, “It's not just about the weight loss—it's about using these compounds as tools for long-term lifestyle changes.”Learn how GLP-1 curbs cravings, supports better eating habits, and the science behind delivery methods like advanced coatings for oral absorption versus injectables. They also dive into maintaining muscle while shedding fat with strategies like resistance training and mindful nutrition.Packed with insights on peptide innovation and safe usage, this episode is a must-watch for anyone dedicated to health, fitness, and personal growth. Don't miss the conversation on using peptides to unlock better results while tackling challenges like muscle mass loss and dosage management!Special perks for our listeners below!